1 Morgan Stanley, Could Obesity Drugs Take a Bite Out of the Food Industry, 2023 2 Morgan Stanley, 2023 3 The Food Institute, 2024 4 Nestle, First-to-market Vital Pursuit Hits Shelves Nationwide, 2024 5 Grocery Dive, How GLP-1s Could Reshape the Grocery Store, 2025 6 MediaRadar, Weight Loss, Diabetes Drug Ad Spending Tops $1B, 2024 7 McKinsey, What are GLP-1 Medications?, 2025 8 JP Morgan Research, The Increase in Appetite for Obesity Drugs, 2023 9 Cornell University, The No-Hunger Games: How GLP-1 Medication Adoption is Changing Consumer Food Demand, 2024
Taken together, there is a need to understand the mechanistic basis of AMI deeper
The ALS drug failed its Phase III PHOENIX trial and could not improve scores on the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale at 48 weeks versus placebo, while falling short of its secondary endpoints
How retatrutide compares to semaglutide and tirzepatide for muscle preservation Comparison drives clarity
Similarly, 55% cover GLP-1s for diabetes only, compared to 57% in 2024 and 49% in 2023
